Vascular Embolization Global Market Report 2023 – By Product (Embolic Agents, Embolization Devices), By Embolization Technique (Coiling Devices, Non-Coiling Devices), By Application (Peripheral Vascular Diseases, Oncology, Urology, Neurology, Other Applications), By End Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Market Size, Trends, And Global Forecast 2023-2032

A vascular stent refers to the small metal mesh tubular scaffolds that are used to prevent acute vessel closure and improve blood flow when a vein or artery is too narrow or blocked, resulting in late restenosis in a variety of vessels, such as coronary arteries. The procedure in which these stents are used is known as "vascular stenting." These stents are placed to widen arteries clogged with deposits and to facilitate fast recovery by reducing the risk of infection and physical trauma. The main products of a vascular stent are coronary stents, peripheral vascular stents, and EVAR stent grafts. The coronary stents are used to treat narrowed coronary arteries that provide the heart with oxygen-rich blood and prevent the artery from closing up again. The term "coronary stent" in the vascular stent market refers to a stent that is a small, metal mesh tube that expands inside a coronary artery and is often placed during or immediately after angioplasty. The various types of vascular stents include bare metal stents, bio-engineered stents, bioresorbable vascular scaffolds, drug-eluting stents, and dual therapy stents that are made of metallic, cobalt-chromium, platinum-chromium, nickel titanium, stainless steel, and polymer materials. The modes of delivery include balloon-expandable stents and self-expanding stents that are used in ambulatory surgical center, cardiac center, and hospitals. The global vascular stent market is segmented - 1) By Product: Coronary Stents, Peripheral Vascular Stents, and Evar Stent Grafts 2) By Type: Bare Metal Stent, Bio-Engineered Stent, Bioresorbable Vascular Scaffold, Drug-Eluting Stent, Dual Therapy Stent 3) By Material: Metallic Stents, Cobalt-Chromium, Platinum-Chromium, Nickel-Titanium, Stainless Steel, Polymer Stents 4) By Mode of Delivery: Balloon-expandable Stent, Self-expanding Stent 5) By End-user: Ambulatory Surgical Center, Cardiac Center, Hospital The global vascular stent market size is expected to grow from $13.42 billion in 2022 to $14.67 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vascular stent market is expected to grow to $20.53 billion in 2027 at a CAGR of 8.8%. Rise in the incidence of vascular diseases will propel the growth of the vascular stent market going forward. Vascular disease refers to an abnormal condition that affects the blood vessels (arteries and veins) and is part of the cardiovascular diseases (CVD) group. The vascular stents help in the treatment of various vascular diseases by enabling the supply of oxygen-rich blood to the heart. For instance, in 2020, according to the Center for Disease Control and Prevention, a US-based federal agency for national public health, approximately 69,700 people died from heart disease, which is 1 in every 5 deaths in the United States. Therefore, an increase in cardiovascular diseases (CVDs) will drive the growth of the vascular stent market. Major players in the vascular stent market are Medtronic Plc., Abbott Laboratories, Boston Scientific Corporation, Biotronik, B. Braun (B. Braun Melsungen), Terumo Corporation, Meril Life Sciences Pvt. Ltd., JOTEC GmbH, W. L. Gore & Associates, Lombard Medical, Microport, Translumina GmbH, Lepu Medical Technology, Philips, Purple Medical Solution Pvt. Ltd., Sahajanand Medical Technologies Pvt. Ltd., Stentys, and Stryker Corporation. Technological advancement is a key trend gaining popularity in the vascular stent market. Many companies are investing in bio-sensing devices, cutting-edge integrated stents, and drug-eluting coronary stent systems to gain a competitive edge in the market. For instance, in 2022, Translumina, an India-based medical equipment manufacturer launched VIVO ISAR, a latest generation dual drug polymer-free coated stent (DDCS) that brings together a stent with a superior safety profile without compromising the drug release kinetics. It uses Probucol, an antioxidant and lipid-lowering drug, as a carrier for releasing Sirolimus (an anti-restenosis drug), and thus creates a polymer-free DES platform with uncompromised safety and efficacy. In 2021, Royal Philips, a Netherlands-based health technology company, acquired Vesper Medical Inc. for an undisclosed amount. With this acquisition, Philips aims to innovate patient treatment with more sophisticated technology and will expand its portfolio of diagnostic, vascular therapy, and therapeutic devices with an advanced venous stent for the treatment of deep venous disease. Vesper Medical Inc. is a US-based medical technology company that develops minimally invasive peripheral vascular devices. North America was the largest region in the vascular stent market share in 2022. The regions covered in the vascular stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vascular stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The vascular stent market consists of sales of bare metal stents, bioresorbable scaffold systems, and drug-eluting balloons. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale along the supply chain, either further along the supply chain or as part of other products. The vascular stent market research report is one of a series of new reports from The Business Research Company that provides vascular stent market statistics, including vascular stent industry global market size, regional shares, competitors with a vascular stent market share, detailed vascular stent market segments, market trends and opportunities, and any further data you may need to thrive in the vascular stent industry. This vascular stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurovascular catheters are medical devices used to treat neurological issues and diseases by providing access to neurovascular organs and the delivery of embolic coils and thrombectomy devices. They are used in minimally invasive therapies to treat blood vessel disorders in the brain, where catheters are manually inserted into the patient's femoral or brachial arteries and guided to the brain to provide treatment that eliminates cutting into the patient's skull and brain tissue. The main types of neurovascular catheters are micro catheters, balloon catheters, access catheters, embolization catheters, and others. Micro catheters are small 0.70-1.30mm diameter catheters used in complex endovascular operations for guidewire support, exchanges, accessing distal anatomy, crossing lesions, delivering therapeutic embolic, injecting contrast media, and performing other procedures and other minimally invasive procedures to deliver gadgets and navigate the human body's complicated vasculature. The major applications are embolic stroke, brain aneurysm, arteriovenous malformations, and others that are used in hospitals, clinics, ambulatory surgical centers, and diagnostic centers. The global neurovascular catheters market is segmented - 1) By Type: Micro catheters, Balloon Catheters, Access Catheters, Embolization Catheters, Other Types 2) By Application: Embolic Stroke, Brain Aneurysm, Arteriovenous Malformations, Other Applications 3) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers The global neurovascular catheters market size is expected to grow from $3.85 billion in 2022 to $4.22 billion in 2023 at a compound annual growth rate (CAGR) of 9.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global neurovascular catheters market size is expected to reach $6.06 billion in 2027 at a CAGR of 9.4%. The rise in the incidence of neurological conditions is expected to propel the growth of the neurovascular catheters market going forward. Neurological problems are diseases that affect the brain as well as the nerves throughout the body and the spinal. Neurovascular catheters are used to diagnose and treat neurological conditions by interventions in the brain and intracranial areas during neurovascular procedures such as neurovascular organs. For instance, according to the report published World Health Organization in 2022, a Switzerland-based organization for public health, one in every four people over the age of 25 is anticipated to have a stroke during their lifetime, whereas every year, 13.7 million people are estimated to have their first stroke, with 5.5 million of them dying as a result. Furthermore, nearly 15 million people worldwide are affected by hemorrhagic stroke, a condition in which a ruptured blood vessel causes bleeding inside the brain. Therefore, the rise in the incidence of neurological conditions drives the growth of the neurovascular catheters market. Major players in the neurovascular catheters market are Medtronic plc., Stryker Corporation, Integra Life Sciences Holdings Corporation, Penumbra Inc., Johnson & Johnson, Terumo Corporation, Acandis GmbH, Biomerics LLC, Zeus Industrial Products Inc., Spiegelberg GmbH & Co. KG, Zimmer Biomet, Concentric Medical, Raumedic AG, Olympus Corporation, and Braun Melsungen AG. Technological innovation is a key trend gaining popularity in the neurovascular catheters market. Major companies operating in the neurovascular catheters market are innovating new products to strengthen their position in the market. For instance, in February 2022, Bendit Technologies, an Israel-based manufacturer innovative catheters introduced Bendit21, steerable micro catheter for treating symptomatic internal carotid artery aneurysm. The Bendit21 steerable micro catheter's three-dimensional clinician-controlled movement and independent control of catheter tip deflection are intended to enable access to difficult-to-reach vascular sites such as coronary, peripheral, and neurovasculature. Additionally, it simplifies the difficult catheterization process into a single step, allowing for speedy and precise results. In January 2022, VitalPath, a US-based manufacturer of catheters and catheter shafts acquired Modern Catheter Technologies for an undisclosed amount. The acquisition will increase VitalPath's capacity for growth, bringing its entire manufacturing footprint to more than 80,000 square feet, including 35,000 square feet of ISO 7 and 8 cleanroom space. Modern Catheter Technologies is a US-based manufacturer of micro catheters used in neurovascular and electrophysiology. North America was the largest region in the neurovascular catheters market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global neurovascular catheters market during the forecast period. The regions covered in global neurovascular catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neurovascular catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The neurovascular catheters market consists of sales of occlusion catheters, stent delivery catheters, diagnostic catheters, guiding catheters, and distal access catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale along the supply chain, either further along the supply chain or as part of other products. The neurovascular catheters market research report is one of a series of new reports from The Business Research Company that provides neurovascular catheters market statistics, including neurovascular catheters industry global market size, regional shares, competitors with a neurovascular catheters market share, detailed neurovascular catheters market segments, market trends and opportunities, and any further data you may need to thrive in the neurovascular catheters industry. This neurovascular catheters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vascular grafts are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular graftsing or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process improves the blood flow by redirecting blood from one area of the body to another. The main products of the vascular grafts market are hemodialysis access graft, endovascular stent graft, peripheral vascular grafts, and coronary artery bypass graft. Endovascular stent graft refers to the method of minimally invasive method that is used to treat an aortic aneurysm and is performed to know the presence of abdominal pain, symptoms for the disease, and also for the size of the aneurysm. The various raw materials are polyester grafts, ePTFE, polyurethane grafts, and biosynthetic grafts. The various applications of vascular grafts are coronary artery disease, aneurysm, vascular occlusion, and renal failure that are used by end-users such as hospitals and ambulatory surgical centres. The global vascular grafts market is segmented - 1) By Product: Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft 2) By Raw Material: Polyester Grafts, ePTFE, Polyurethane Grafts, Biosynthetic Grafts 3) By Application: Coronary Artery Disease, Aneurysm, Vascular Occlusion, Renal Failure 4) By End-User: Hospitals, Ambulatory Surgical Centers The global vascular grafts market size grew from $2.96 billion in 2022 to $3.21 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global vascular grafts is expected to grow from $4.37 billion in 2027 at a CAGR of 8.1%. The rising prevalence of vascular diseases is driving the growth of the global vascular grafts market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world and according to the American Heart Association (AHA), the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market. Major players in the vascular grafts market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic PLC., Getinge, Terumo Medical Corporation, and Gore Medical. The high cost of medical treatment and complications related to prosthetic grafts are expected to restrain global vascular graftss market growth. The cost of the CABG (coronary artery bypass graft) surgery is very high in western countries. For instance, in the US, the average cost of coronary artery bypass surgery is $40,000, which varies widely by region and facility. Moreover, several complications are associated with prosthetic grafts such as disruption of an infected anastomotic suture line due to rupture or pseudoaneurysm formation, sepsis, amputation, thromboembolism, chances of reinfection due to vascular graftss reconstruct, enteric fistulae, the spread of bacterial infection to other sites, and death. Thus, high treatment costs and complications related to prosthetic grafts are expected to restrain the market growth. Companies in the vascular grafts market are increasingly investing in technological advances for the development of innovative vascular graftss, including customization of vascular graftss. For instance, RelayPro, a thoracic stent graft system recently launched by Terumo Aortic, is a low-profile device designed for patients with smaller access vessels in the treatment of thoracic endovascular aortic repair (TEVAR). It offers a broad range of diameters, lengths, tapers, and proximal configurations to the physicians. Both bare stent and non-bare stent (NBS) versions are available for this device and they can be customized to meet the patient’s specific anatomical needs. In June 2020, LeMaitre Vascular, a US-based medical device company, acquired Artegraft for $90 million. The acquisition the company expected to extend its product line with Artegraft’s innovative products and better serve the customers’ needs. Artegraft is a New Jersey-based seller of vascular graftss. North America was the largest region in the vascular grafts market in 2022. Western Europe was the second largest region in the vascular grafts market report. The regions covered in the vascular grafts industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vascular grafts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The vascular graftss market consists of sales of polytetrafluoroethylene (Teflon), polyethylene terephthalate (Dacron), or a different person's vein (allograft). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The vascular grafts market research report is one of a series of new reports from The Business Research Company that provides vascular grafts market statistics, including vascular grafts industry global market size, regional shares, competitors with a vascular grafts market share, detailed vascular grafts market segments, market trends and opportunities, and any further data you may need to thrive in the vascular grafts industry. This vascular grafts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumours to spread via the bloodstream and receive more oxygen and nutrients. The main types of vascular endothelial growth factor (VEGF) inhibitors are Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different routes of administration include oral, and intravenous and are used in oncology, ophthalmology, and others. The global vascular endothelial growth factor (VEGF) inhibitor market is segmented - 1) By Drugs Type: Avastin, Tecentriq, Cometriq, Eylea, Other Drug Types 2) By Route Of Administration: Oral, Intravenous 3) By Application: Oncology, Ophthalmology, Other Applications The global vascular endothelial growth factor (VEGF) inhibitor market size grew from $8.27 billion in 2022 to $8.96 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the vascular endothelial growth factor (vegf) inhibitor is expected to grow from $12.11 billion in 2027 at a CAGR of 7.8%. The growing prevalence of cancer and macular degeneration diseases is expected to drive the VEGF inhibitor market. For instance, in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, age-related macular degeneration will affect 8–7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. A vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the vascular endothelial growth factor (VEGF) inhibitor market growth over the forecast period. Major players in the vascular endothelial growth factor (VEGF) inhibitor market are Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca PLC., Bayer AG, Eli Lilly and Company and Allergan PLC. Side effects caused by VEGF inhibitors are expected to hinder the vascular endothelial growth factor (VEGF) inhibitor market. Side effects of treatment with VEGF-targeting angiogenesis inhibitors include hemorrhage and clots in the arteries, which results in a stroke or heart attack, hypertension, reversible posterior leukoencephalopathy syndrome, and impaired wound healing, and protein in the urine. For instance, Bevacizumab, a biosimilar drug approved by FDA, has side effects such as impaired wound healing, hypertension, bleeding, and gastrointestinal perforations. Side effects caused by VEGF inhibitors hinder the VEGF inhibitor market growth. Key players operating in the VEGF inhibitor industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For instance, in May 2020, AbbVie, a US-based biopharmaceutical company acquired Allergan, Inc., a US-based pharmaceutical company focused on eye care. This acquisition establishes a biopharma firm with leadership roles in vital therapeutic areas such as hematologic oncology, immunology, Allergan Aesthetics, and neuroscience. Furthermore, in January 2020, Exonate, a biotechnology company, collaborated with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson for the development of a new eye drop for the treatment of retinal vascular diseases. Exonerate developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. In May 2020, AbbVie Inc., a US-based biopharmaceutical company, acquired Allergan plc for an amount of $63 billion. This acquisition is expected to give AbbVie Inc. an enhanced long-term growth potential along with a growing dividend and investment in innovation in each of Allergan plc’s therapeutic categories. Allergan plc is an Ireland-based pharmaceutical company engaged in the manufacturing of drugs and medical devices in the field of eye care, medical aesthetics, gastroenterology, and the central nervous system. North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2022. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the global vascular endothelial growth factor (VEGF) inhibitor market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor. The main types of tumor embolization devices are radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents involve gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA) used in the treatment of tumors. The applications involved are cancer tumors and noncancerous tumors that are used by various end-users such as hospitals, cancer treatment centers, intensive care units, and surgical centers. The global tumor embolization devices market is segmented - 1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents 2) By Application: Cancer Tumors, Noncancerous Tumors 3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers The global tumor embolization devices market size grew from $1.44 billion in 2022 to $1.61 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the tumor embolization devices is expected to grow from $2.5 billion in 2027 at a CAGR of 11.6%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the tumor embolization devices market during the forecast period. According to the American Cancer Society, there were about 1.9 million new cases and 608,570 cancer deaths in 2021 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the tumor embolization market over the forthcoming years. Major players in the tumor embolization devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Sirtex Medical Ltd., Merit Medical, Cook Meidical LLC., BTG PLC., Angiodynamics, and Siemens Healthineers. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to advanced therapies and advanced therapy medicinal products. These regulations include changes to equipment approval procedures and other aspects. For instance, the United States Food and Drug Administration is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the tumor embolization devices market growth. Companies in the tumor embolization devices market are increasingly investing in technological advances to provide more efficient devices to consumers. The advances include the emergence of biocompatible, biodegradable, drug-eluting microspheres that provide effective embolization. Bioresorbable microspheres block the blood vessels causing tumors without long-term blockage of the healthy tissue blood vessels. In May 2021, Emboline received an investment of $55 m to develop and launch embolic protection catheters from Matrix Capital Management. In Boston Scientific, a US-based medical device manufacturer, acquired Obsidio Inc. for an undisclosed amount. The acquisition would help Boston Scientific to expand its interventional oncology and embolization portfolio. Obsidio is a US-based developer of Embolization gel. North America was the largest region in the tumor embolization devices market in 2022. Asia-Pacific was the second largest region in the global tumor embolization devices market share. The regions covered in the global tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor embolization devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor embolization devices market consists of sales of radioembolic agents and non-radioactive embolic agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The tumor embolization devices market research report is one of a series of new reports from The Business Research Company that provides tumor embolization devices market statistics, including tumor embolization devices industry global market size, regional shares, competitors with a tumor embolization devices market share, detailed tumor embolization devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor embolization devices industry. This tumor embolization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interventional neurology devices and equipment are used to treat neurovascular diseases such as aneurysms, arteriovenous malformations, cavernous malformations, and stroke. The main types of interventional neurology devices and equipment are aneurysm coiling and embolization devices, cerebrospinal fluid management devices, neuro thrombectomy devices, and support devices. The neuro thrombectomy devices are used to perform mechanical thrombus removal from intracranial arteries angiographically. The aneurysm coiling and embolization devices types are embolic coils, flow diversion devices, and liquid embolic devices. The angioplasty devices types are carotid artery stents and embolic protection systems. The support devices types are micro guidewires and microcatheters. The neurothrombectomy device types are clot retrieval devices, suction and aspiration devices, and snares. The various end-users are hospitals, neurology clinics, ambulatory care centres, and others. The global interventional neurology devices and equipment market is segmented - 1) By Type: Aneurysm Coiling & Embolization Devices, Cerebrospinal Fluid Management Devices, Neurothrombectomy Devices, Support Devices 2) By End-User: Hospitals, Neurology clinics, Ambulatory care centers and others 3) Aneurysm Coiling & Embolization Devices By Type: Embolic coils, Flow diversion devices, Liquid embolic devices 4) Angioplasty Devices by Type: Carotid artery stents, Embolic protection systems 5) Support Devices By Type, Micro guide wires, Micro catheters 6) Neurothrombectomy Devices By Type: CLOT retrieval devices, Suction and aspiration devices, Snares The global interventional neurology devices and equipment market size will grow from $1.99 billion in 2022 to $2.17 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the interventional neurology devices and equipment is expected to grow to $2.97 billion in 2027 at a CAGR of 8.1%. An increase in the patient population with neurological disorders is driving the Interventional neurology devices market. Neural disorders like Alzheimer's disease, cerebrovascular diseases including stroke, migraine, and other headache disorders are on the rise. The rapid increase in the geriatric population, high-stress levels in young individuals, and head injuries due to accidents are the main reasons for neural disorders. For example, according to the Brain Aneurysm Foundation, it is estimated that in the United States, 6 million people suffer from unruptured brain aneurysms. Also, according to World Health Organization, more than 50 million have epilepsy and over 47 million have dementia. Hence, the rapid increase in the incidence of neurological disorders is slated to boost the interventional neurology devices and equipment market in the forecast period. Major players in the interventional neurology devices and equipment market are Medtronic, Stryker, Terumo Corporation, Penumbra, COVIDien, Abbott, Merit Medical Systems, Johnson & Johnson Services Inc., W. L. Gore & Associates, and Bayer AG. Strict regulatory policies by the US FDA for the approval of Interventional Neurological Devices will hinder the interventional neurological devices market growth. FDA approves the devices based on the class of the devices. Most of the devices under Interventional Neurological Devices are classified under the class 3 devices. Class 3 devices are required to undergo a lot of approvals from the regulatory bodies which is a time-consuming process. For example, the approval for the class 3 devices may take more than 36 months, thereby increasing the overall cost of product development, impacting the interventional neurology devices and equipment market negatively. Stryker Inc.’s latest technological development Neuroform Atlas Stent System is expected to provide significant results to treat brain aneurysms with embolic coils. The introduction of such technologies would drive the interventional neurological device market in the future. The Atlas stent system provides great support during the coiling procedures and it has been designed s to provide the coil support and wall apposition needed to perform an effective stent-assisted coiling procedure. Neuroform Atlas has enhanced stent conformability, a low-profile delivery system, and high deployment accuracy even in distal anatomy making it the latest choice of the neuro-surgeons, thereby steering the interventional neurology devices and equipment market. The United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) presides over the regulation and approval of medical devices in the USA. Within CDRH, the Division of Neurological and Physical Medicine Devices reviews medical technologies that interface with the central and peripheral nervous system (neurotechnologies), including neuro-interventional medical devices that are used in the treatment of stroke. Also, the division of Neurological and Physical Medicine Devices (DNPMD) serves as the primary point of review at the FDA for regulatory submissions involving medical device neurotechnologies. Although the process of approval is strenuous and the time taken is too long, the devices approved by FDA have had a major impact on the markets and the products approved by FDA are successful. FDA has been actively approving devices in the interventional neurosurgery device division which has boosted the market’s growth. For example, approval of Stryker’s Neuroform Atlas Stent System, De Novo clearance for Nerivio Migra, and Pipeline Flex embolization by Medtronic are the recent approvals made by FDA which enhances the interventional neurology devices and equipment market growth. North America was the largest region in the global interventional neurology devices and equipment market in 2022. Asia-Pacific was the second-largest region in the interventional neurology devices and equipment market share. The regions covered in the global interventional neurology devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional neurology devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The interventional neurology devices and equipment market consists of sales of instruments such as carotid artery stents, embolic protection systems, micro guide wires, and micro catheters. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The interventional neurology devices and equipment market research report is one of a series of new reports from The Business Research Company that provides interventional neurology devices and equipment market statistics, including interventional neurology devices and equipment industry global market size, regional shares, competitors with a interventional neurology devices and equipment market share, detailed interventional neurology devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the interventional neurology devices and equipment industry. This interventional neurology devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interventional oncology devices are used in the diagnosis and treatment of cancer using minimally invasive techniques and advanced imaging technology. The main products of interventional oncology devices are embolization devices, ablation devices, and support devices. The embolization devices are intended for the embolization of the blood vessels of a variety of tumors. The interventional oncology devices are used to perform procedures such as thermal tumour ablation, non-thermal tumour ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE), or bland embolization, that are used to treat cancer types such as liver cancer, kidney cancer, lung cancer, bone cancer, and others. The global interventional oncology devices market is segmented - 1) By Product: Embolization Devices, Ablation Devices, Support Devices 2) By Procedure: Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT), Transcatheter Arterial Embolization (TAE) or Bland Embolization 3) By Cancer Type: Liver Cancer, Kidney Cancer, Lung Cancer, Bone Cancer, Other Cancer Types The global interventional oncology devices market size will grow from $2.21 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the interventional oncology devices is expected to grow from $3.03 billion in 2027 at a CAGR of 6.5%. The availability of private and government funding drove the interventional oncology devices market. In the field of cancer, funding from the government and private has increased, especially for the devices used in treatments as it promotes early detection and better survival rates. The American Cancer Society, the largest non-government, not-for-profit cancer research funder, has awarded 630 projects with a grant amount of $384,262,652 in 2021. BioProtect Ltd., an Israeli company that develops novel bioabsorbable polymer spacer balloons, received a funding of $13 million of its Series D equity financing from a leading global syndicate of venture investors that finances the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. Endosight, the first augmented-reality-guided ablative system, has received 20% of its funding from private organizations. The funding from government and private organizations helps in the development of new technologies and devices, thereby driving the interventional oncology devices market. Major players in the interventional oncology devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Merit Medical Systems Inc., Philips Volcano, AngioDynamics Inc., GE Healthcare, Siemens Healthineers, Sirtex Medical, and Cook Medical Incorporated. Rising product recalls are likely to hinder the demand for interventional oncology devices. The number of interventional oncology product recalls has risen. For instance, in June 2020, the IceFORCE 2.1 CX Prostate Cryoablation Kit Visual ICE System of the Boston Scientific Corporation was recalled as the needle surface had deteriorated. In March 2020, Medtronic recalled the Pipeline Flex embolization system with Shield technology due to a fracture in the distal portion. These product recalls put financial strain on businesses and also hampers the demand, thus hindering the interventional oncology devices market. Companies are focusing on deploying robotics technology in interventional oncology devices, for higher efficiency. The robotic system integrates image-based planning and navigation with the installation of different instruments to the desired body part with better accuracy and efficiency. For instance, in March 2022, the U.S. Food and Drug Administration approved Quantum Surgical’s Epione interventional oncology robotics platform. In July 2020, Terumo Corporation, a Japanese medical device company, acquired Quirem Medical for $45 million. Through this acquisition, Terumo intends to launch the Holmium platform globally as a part of the ongoing expansion of its interventional oncology (IO) portfolio. It further strengthens the brand and extends manufacturing and clinical development activities. Quirem Medical is a Netherlands-based medical device company that develops and markets Holmium-166-based radioactive microspheres for Selective Internal Radiation Therapy (SIRT). North America was the largest region in the interventional oncology devices market in 2022. Asia-Pacific was the second largest region in the global interventional oncology devices market analysis. The regions covered in the global interventional oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The interventional oncology devices market research report is one of a series of new reports from The Business Research Company that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intracranial stents are tubular device that is placed inside the blood vessel, canal, or duct. They are used for intracranial stenosis and brain aneurysms to open the blocked arteries. The main types of intracranial stents are self-expanding stents, balloon expanding stents, and stent-assisted coil embolization. A self-expanding stent expands on its own after being inserted into the lumen it is meant to occupy, such as a blood vessel, tube, or organ. Balloon expanding stents also known as balloon-expandable stents have higher radial stiffness and more accurate placement and are designed to treat restenosis in the iliac artery by opening clogged arteries and restoring blood flow. Stent-assisted coil embolization helps stabilize the coils within the aneurysm and provide a buttress that allows for coil deposition while preventing coil haerniation into the parent vessel lumen. The various indications of diseases include brain aneurysm, intracranial stenosis and are implemented in various sectors such as hospitals, ambulatory surgery centers, and others. The global intracranial stents market is segmented – 1) By Type: Self Expanding Stents, Balloon Expanding Stents, Stent-Assisted Coil Embolization 2) By Disease Indication: Brain Aneurysm, Intracranial Stenosis 3) By End-User: Hospitals, Ambulatory Surgery Centers, Other End-Users The global intracranial stents market size grew from $0.36 billion in 2022 to $0.43 billion in 2023 at a compound annual growth rate (CAGR) of 18.7. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of intracranial stents is expected to grow to $0.73 billion in 2027 at a CAGR of 14.2%. The increase in incidence of a brain aneurysm is expected to propel the growth of the intracranial stents market in the coming years. A brain aneurysm is the development of a bulge in the blood vessels of the brain. This bulge may rupture or burst and can cause brain hemorrhage, which may lead to the death of the patient. Intracranial vessel stenting (IVS) is a minimally invasive treatment for treating serious cerebral artery stenosis. The weakening of the arteries that deliver blood to the brain is known as cerebral artery stenosis. According to the brain aneurysm foundation, by 2020, an expected 6.5 million people in the USA are suffering from an unruptured brain aneurysm, accounting for about one in every 50 people. Additionally, a brain aneurysm causes around 500,000 deaths globally every year and is more common among women. Thus, the increasing incidence of a brain aneurysm will drive the intracranial stents market growth. Major players in the intracranial stents market are Medtronic, Balt, Stryker Corporation, MicroPort Scientific Corporation, Boston Scientific Corporation, Acandis GmbH, Admedes Schuessler GmbH, MicroVention (Terumo), and Phenox. The introduction of flow diversion technology to the field of neurointervention has revolutionized the treatment of intracranial aneurysms which is a key trend gaining popularity in the intracranial stents market. Flow diversion is an endovascular procedure in which a device is inserted in the parent blood vessel to move blood flow away from the aneurysm rather than around the aneurysm sac. For instance, in March 2020, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) developed an innovative intracranial flow diverter stent for brain aneurysms treatment. Intracranial flow diverters have the benefit of becoming adaptable and flexible to the vessel's shape and direction and also helps the vessel wall recover by relieving it of the continuous burden of blood flow. It is entitled as Chitra flow diverter, the device is ready for transfer and further testing in animals to be followed by human trials. In January 2021, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institute of the Department of Science & Technology (DST), Govt of India, under the Technical Research Centre (TRC), announced that it has entered into Technology Transfer Agreements with Biorad Medisys, for two biomedical implant devices namely an Atrial Septal Defect Occluder and an Intracranial Flow Diverter Stents developed by the institute in collaboration with National Aerospace Laboratories, Bangalore (CSIR-NAL)using superelastic NiTiNOL alloys. Biorad Medisys is an India-based company that manufactures various implants and surgical devices. North America was the largest region in the intracranial stents market in 2022. Asia-Pacific is expected to be the fastest region in the intracranial stents market share during the forecast period. The regions covered in the intracranial stents market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the intracranial stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The intracranial stents market consists of sales of Neuroform stents, Solitaire, Enterprise, and Leo plus, and Wingspan stent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The intracranial stents market research report is one of a series of new reports from The Business Research Company that provides intracranial stents market statistics, including intracranial stents industry, intracranial stents global market size, regional shares, competitors with intracranial stents market share, detailed intracranial stents market segments, market trends and opportunities, and any further data you may need to thrive in the intracranial stents industry. This intracranial stents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.